摘要

【摘要】
目的 探讨疏肝解郁胶囊联合草酸艾司西酞普兰治疗脑卒中患者焦虑抑郁状态的临床疗效。

方法 选取本院2015年1月～2015年12月本院收治的118例脑卒中后并发抑郁焦虑的患者随机分为联合组、对照组各59例，两组均给予草酸艾司西酞普兰治疗，联合组加用疏肝解郁胶囊治疗，治疗周期3个月，对比两组临床效果。

结果 治疗前，联合组和对照组的HAMA、HAMD评分差异均无统计学意义（P>0.05）；治疗1个月、3个月后，两组患者的HAMA、HAMD评分较治疗前均显著的降低（P<0.05），联合组的HAMA、HAMD评分均显著的低于对照组（P<0.05）；治疗后，联合组的NPY评分均显著的低于对照组、SP显著的高于对照组（P<0.05），联合组的血清IL-1β、IL-6、TNF-α水平均显著的低于对照组（P<0.05）。

结论 疏肝解郁胶囊联合草酸艾司西酞普兰治疗脑卒中患者焦虑抑郁具有更加显著的临床效果。

关键词：【关键词】疏肝解郁胶囊；草酸艾司西酞普兰；脑卒中；焦虑；抑郁

ABSTRACT

【Abstract】
ObjectiveTo investigate the clinical curative effect of Shugan Jieyu capsule combined with oxaliplatin in treatment of cerebral apoplexy patients with Ai Sciplan anxiety depression.

MethodsSelected the hospital in January 2015 ~ December 2015 in our hospital from 118 cases of stroke complicated with depression and anxiety of the patients were randomly divided into combined group and control group (n = 59). Two groups were given escitalopram oxalatetreatment , using Shugan Jieyu capsule in the treatment of and in combination group and treatment period of 3 months, compared two groups of clinical effect.

ResultsBefore treatment, combination group and control group of HAMA, HAMD score differences had no statistical significance (P > 0.05), 1 month, 3 months after treatment, compared with before treatment, two groups of patients with HAMA, HAMD score were significantly decreased (P < 0.05), the combined group of HAMA and HAMD scores were significantly lower than control group (P < 0.05). After treatment, the NPY score in the combination group were significantly lower than control group, SP significantly higher than the control group (P < 0.05), combination group of serum IL-1 P, IL-6 and TNF alpha levels were significantly below the control group (P < 0.05).

Conclusion   Shuganjieyu capsule combined with oxaliplatin in treatment of cerebral stroke patients with Ai Sciplan anxiety depression has more significant clinical effect.

Key words: 【Key words】Shugan Jieyu capsule; oxalate Ai Sciplan; stroke; anxiety; depression